Inogatran (H-314-27) is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases.

Product information

CAS Number: 155415-08-0

Molecular Weight: 438.56

Formula: C21H38N6O4

Chemical Name: 2-{[(2R)-1-[(2S)-2-[(3-carbamimidamidopropyl)carbamoyl]piperidin-1-yl]-3-cyclohexyl-1-oxopropan-2-yl]amino}acetic acid

Smiles: NC(=N)NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@@H](CC1CCCCC1)NCC(O)=O

InChiKey: CDPROXZBMHOBTQ-SJORKVTESA-N

InChi: InChI=1S/C21H38N6O4/c22-21(23)25-11-6-10-24-19(30)17-9-4-5-12-27(17)20(31)16(26-14-18(28)29)13-15-7-2-1-3-8-15/h15-17,26H,1-14H2,(H,24,30)(H,28,29)(H4,22,23,25)/t16-,17+/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

Inogatran (H-314-27; 0.075, 0.25, 0.75 mg/kg, i.v.) results in dose-dependent increases in activated partial thromboplastin time (aPTT), thrombin time (TT), and prothrombin time (PT) in a canine electrolytic injury model of venous thrombosis. Inogatran dose-dependently inhibits thrombus formation, which is measured as an increase in time to occlusion (TTO) and a decrease in thrombus weight. Inogatran also improves vena caval blood flow and reduces the overall incidence of thrombotic occlusion in a rat model.

Products are for research use only. Not for human use.